Shuttle Pharma Achieves Compliance with Nasdaq Minimum Bid Price Requirement
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) is a specialty pharmaceutical company in the discovery and development stage, dedicated to enhancing the outcomes for cancer patients receiving radiation therapy. Recently, Shuttle Pharma announced that it has successfully regained compliance with Nasdaq Listing Rule 5550(a)(2), commonly referred to as the Minimum Bid Price Rule. Nasdaq's notice confirmed that the company's share price has surpassed $1.00 for ten consecutive trading days, thereby meeting the necessary listing requirement.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members from Georgetown University Medical Center, Shuttle Pharma is focused on developing therapies that improve the effectiveness of radiation therapy (RT). The company’s mission is to enhance the lives of cancer patients by creating treatments that maximize the efficacy of RT while minimizing its side effects. Radiotherapy is a cornerstone of cancer treatment, and Shuttle Pharma’s research into radiation sensitizers aims to increase cancer cure rates, extend patient survival, and improve the quality of life for those undergoing primary treatment or receiving additional therapies like chemotherapy and immunotherapy.
Shuttle Pharma's Dedication to Cancer Care
Shuttle Pharma's commitment goes beyond mere compliance; it is about advancing scientific knowledge and improving clinical outcomes. The company is actively engaged in developing innovative treatments that cater to the needs of cancer patients, ensuring these needs remain central to pharmaceutical development. Through its focused research initiatives, Shuttle Pharma aims to fill significant gaps in existing cancer therapies.
Looking Ahead: Future Prospects and Strategic Direction
As Shuttle Pharma continues to evolve, maintaining compliance with stock exchange regulations is vital for fostering investor confidence and supporting future fundraising efforts. By adhering to and surpassing the Minimum Bid Price Rule, the company showcases its stability and positive growth trajectory, which can significantly benefit its shareholders. Shuttle Pharma is well-positioned to capitalize on its research and development advancements to attract new investors and forge collaborations within the healthcare sector.
Contact Information
For further inquiries, you can reach out to Shuttle Pharmaceuticals directly:
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
Email: info@shuttlepharma.com
Investor Relations
Investor relations are managed by Lytham Partners, LLC. For any investment-related questions, please contact Robert Blum at:
Lytham Partners, LLC
Phone: 602-889-9700
Email: shph@lythampartners.com
Frequently Asked Questions
What recent milestone has Shuttle Pharma achieved?
Shuttle Pharma has regained compliance with Nasdaq's Minimum Bid Price Rule, allowing it to keep its stock listing intact.
When did Shuttle Pharma confirm its compliance?
The company received confirmation from Nasdaq after trading above the $1.00 threshold for ten consecutive days.
What is Shuttle Pharmaceuticals' primary objective?
The main goal of Shuttle Pharma is to enhance outcomes for cancer patients by developing therapies that improve the effectiveness of radiation therapy while minimizing side effects.
Where can I find additional information about Shuttle Pharma?
You can find more details on the company's official website.
Who should I contact regarding investor inquiries?
For any investor-related questions, you can reach out to Robert Blum at Lytham Partners, LLC.
